Compared to Estimates, Albemarle (ALB) Q1 Earnings: A Look at Key Metrics

07.05.26 00:00 Uhr

Werte in diesem Artikel
Aktien

114,55 EUR 0,25 EUR 0,22%

Indizes

1.854,4 PKT -8,4 PKT -0,45%

7.440,4 PKT 86,4 PKT 1,18%

Albemarle (ALB) reported $1.43 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 32.7%. EPS of $2.95 for the same period compares to -$0.18 a year ago.The reported revenue represents a surprise of +7.83% over the Zacks Consensus Estimate of $1.33 billion. With the consensus EPS estimate being $1.24, the EPS surprise was +138.79%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Albemarle performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net Sales- Specialties: $358.41 million versus the four-analyst average estimate of $319.07 million. The reported number represents a year-over-year change of +11.7%.Net Sales- Energy Storage: $891.17 million compared to the $775.27 million average estimate based on four analysts. The reported number represents a change of +69.9% year over year.Adjusted EBITDA- Specialties: $76.13 million versus $55.13 million estimated by four analysts on average.Adjusted EBITDA- Energy Storage: $551.36 million versus $295.84 million estimated by four analysts on average.View all Key Company Metrics for Albemarle here>>>Shares of Albemarle have returned +12.3% over the past month versus the Zacks S&P 500 composite's +10.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Albemarle und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Quelle: Zacks

Nachrichten zu Albemarle Corp.

Analysen zu Albemarle Corp.

DatumRatingAnalyst
16.11.2017Albemarle HoldDeutsche Bank AG
10.11.2017Albemarle OutperformRBC Capital Markets
09.11.2017Albemarle NeutralUBS AG
27.10.2017Albemarle OutperformBMO Capital Markets
25.09.2017Albemarle NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
10.11.2017Albemarle OutperformRBC Capital Markets
27.10.2017Albemarle OutperformBMO Capital Markets
08.05.2017Albemarle OutperformRBC Capital Markets
17.03.2017Albemarle OutperformRBC Capital Markets
01.03.2017Albemarle OutperformRBC Capital Markets
DatumRatingAnalyst
16.11.2017Albemarle HoldDeutsche Bank AG
09.11.2017Albemarle NeutralUBS AG
25.09.2017Albemarle NeutralRobert W. Baird & Co. Incorporated
10.03.2016Albemarle NeutralSeaport Global Securities
03.02.2015Albemarle Market PerformCowen and Company, LLC
DatumRatingAnalyst
16.08.2011Albemarle underperformOppenheimer & Co. Inc.
04.01.2006Update Albemarle Corp.: UnderweightJP Morgan

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Albemarle Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen